A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies
A study for patients with advanced malignancies using study drug REGN2810 in combination with other anti-cancer therapies
Sponsor: Regeneron
Enrolling: Male and Female Patients
IRB Number: AAAP2403
U.S. Govt. ID: NCT02383212
Contact: Cristian Barquero: 646-317-6041 / cb3180@cumc.columbia.edu
Additional Study Information: This study is being done to find a safe dose level of REGN2810 alone and in combination with radiotherapy, cyclophosphamide, and radiotherapy plus cyclophosphamide together. Other purposes of this study are to measure the levels of REGN2810 in particpants blood and to collect any evidence of anti-tumor activity of REGN2810 when given alone or in combination with the other therapies. REGN2810 is a fully human monoclonal anti - PD-1 antibody (a type of protein) that works by blocking the programmed death receptor 1 (PD-1), a cell receptor on immune cells that is involved in preventing the immune cells from destroying other cells. This study is being done to test the safety of REGN2810 and to see if blocking PD-1 with REGN2810 will help the immune system attack the tumor.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Do you have an advanced solid tumor? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Cristian Barquero